Advertisement
Advertisement
U.S. Markets closed
S&P Futures
3,902.00 +4.25 (+0.11%) Dow Futures
31,241.00 +39.00 (+0.12%) Nasdaq Futures
11,838.00 -40.25 (-0.34%) Russell 2000 Futures
1,771.50 -3.40 (-0.19%) Crude Oil
110.35 +0.46 (+0.42%) Gold
1,845.10 +3.90 (+0.21%)
Johnson & Johnson (JNJ)
NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
Advertisement
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 173.94 |
| Open | 174.85 |
| Bid | 176.70 x 1000 |
| Ask | 176.61 x 1200 |
| Day's Range | 174.07 - 177.15 |
| 52 Week Range | 155.72 - 186.69 |
| Volume | |
| Avg. Volume | 7,883,030 |
| Market Cap | 465.918B |
| Beta (5Y Monthly) | 0.72 |
| PE Ratio (TTM) | 26.45 |
| EPS (TTM) | 6.69 |
| Earnings Date | Apr 18, 2022 - Apr 22, 2022 |
| Forward Dividend & Yield | 4.52 (2.56%) |
| Ex-Dividend Date | May 23, 2022 |
| 1y Target Est | 191.42 |
- Benzinga
ImmixBio's Lead Candidate Shows Improved Survival Over FDA-Approved Soft Tissue Cancer Drug
Immix Biopharma Inc (NASDAQ: IMMX) announced positive interim data from an animal study in Soft Tissue Sarcoma (STS). STS is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). After one treatment cycle, ImmixBio's lead candidate IMX-110 produced 75% survival vs. 0% survival for trabectedin in a connective tissue cancer Soft Tissue Sarcoma (STS) mice study. Trabectedin is sold as Yondelis by Janssen, a Johnson & Johnson (NYSE: JNJ) com
- Zacks
Best ETFs for High Inflation and Rising Rates
We discuss areas that could outperform in the current market environment.
- MoneyWise
How can I stop the pain and make money in this nightmarish market? BofA says this is the ‘best hope’ for bulls in 2022
Companies could be returning trillions to shareholders. Here’s how to accept it.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
